FIELD: medicine.
SUBSTANCE: invention concerns using humanised anti-interleukin-6 receptor (IL-6R) antibodies, which block the IL-6 signal transport and inhibit the biological activity of Il-6 for producing a therapeutic agent for systemic-onset juvenile rheumatoid arthritis.
EFFECT: more effective treatment of systemic-onset juvenile rheumatoid arthritis.
8 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR DISEASES, RELATED TO CHILDREN'S CHRONIC ARTHRITIC DISEASES | 2002 |
|
RU2361613C2 |
| METHOD OF TREATING INTERLEUKIN-6-DEPENDENT DISEASES | 2004 |
|
RU2509574C2 |
| PROPHYLACTIC DRUG FOR VASCULITIS | 2004 |
|
RU2379054C2 |
| THERAPEUTIC AGENT IN SPINAL MARROW INJURY CONTAINING INTERLEUKINE-6 ANTAGONIST | 2004 |
|
RU2358761C2 |
| CHRONIC REJECTION INHIBITOR | 2008 |
|
RU2450829C2 |
| DRUGS AGAINST CHRONIC RHEUMATIC ARTHRITIS CONTAINING ANTAGONIST OF IL-6 AS EFFECTIVE COMPONENT | 1995 |
|
RU2147443C1 |
| THERAPEUTIC AGENT FOR MESOTHELIOMA | 2004 |
|
RU2392967C2 |
| PROPHYLACTIC OR THERAPEUTIC AGENT FOR TREATING INFLAMMATORY INTESTINAL DISEASES CONTAINING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT | 1999 |
|
RU2195960C2 |
| AGENT FOR CARDIOPATHY | 2006 |
|
RU2450830C2 |
| AGENTS FOR SUPPRESSING TRANSPLANTED ISLAND DAMAGE FOLLOWING ISLAND TRANSPLANTATION | 2006 |
|
RU2446826C2 |
